Ubs Asset Management Americas Inc Atreca, Inc. Transaction History

Ubs Asset Management Americas Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	BUY	$4.91 - $9.07 $90,432 - $167,051	18,418 Added 37.67%	67,312 $419,000
Q2 2021 Aug 16, 2021	SELL	$7.82 - $13.8 $2.02 Million - $3.57 Million	-258,654 Reduced 84.1%	48,894 $416,000
Q1 2021 May 14, 2021	BUY	$13.0 - $19.34 $77,402 - $115,150	5,954 Added 1.97%	307,548 $4.71 Million
Q4 2020 Mar 01, 2021	SELL	$13.03 - $17.09 $66,479 - $87,193	-5,102 Reduced 1.66%	301,594 $4.87 Million
Q3 2020 Nov 13, 2020	BUY	$12.67 - $23.19 $3.89 Million - $7.11 Million	306,696 New	306,696 $4.28 Million

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.